The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Repurposing metformin for the prevention of cancer and cancer recurrence
Open accessAbstract
Multiple epidemiological studies have documented an association between metformin, used for treatment of type 2 diabetes, and reduced cancer incidence and mortality. Cell line models may not accurately reflect the effects of metformin in the clinical setting. Moreover, findings from animal model studies have been inconsistent, whilst those from more recent epidemiological studies have tempered the overall effect size. The purpose of this review is to examine metformin’s chemopreventive potential by outlining relevant mechanisms of action, the most recent epidemiologic evidence, and recently completed and ongoing clinical trials. Although repurposing drugs with excellent safety profiles is an appealing strategy for cancer prevention and treatment in the adjuvant setting, there is no substitute for well-executed, large randomised clinical trials to define efficacy and determine the populations that are most likely to benefit from an intervention. Thus, enthusiasm remains for understanding the role of metformin in cancer through ongoing clinical research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Srimaroeng, C., Cecile, J. P., Walden, R., & Pritchard, J. B. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350077 · Cited by 2,989
Hirsch, H. A., Iliopoulos, D., Tsichlis, P. N., & Struhl, K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2994 · Cited by 1,115
Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis
Wheaton, W. W., Weinberg, S. E., Hamanaka, R. B., Soberanes, S., Sullivan, L. B., Anso, E., Glasauer, A., Dufour, E., Mutlu, G. M., Budigner, G. S., et al. (2014) · eLife · doi:10.7554/elife.02242 · Cited by 1,105 · cited 1×
“In human cancer cell lines, which are known to express OCT1, metformin has been shown to decrease cell proliferation through inhibition of complex I [12].”
Metformin: historical overview
Bailey, C. J. (2017) · Diabetologia · doi:10.1007/s00125-017-4318-z · Cited by 1,055
Fasting Insulin and Outcome in Early-Stage Breast Cancer: Results of a Prospective Cohort Study
Goodwin, P. J., Ennis, M., Pritchard, K. I., Trudeau, M. E., Koo, J., Madarnas, Y., Hartwick, W., Hoffman, B., & Hood, N. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.42 · Cited by 981
Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
DeCensi, A., Puntoni, M., Goodwin, P., Cazzaniga, M., Gennari, A., Bonanni, B., & Gandini, S. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0157 · Cited by 918
Self-citationSahra, I. B., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J. F., Le Marchand-Brustel, Y., & Bost, F. (2008) · Oncogene · doi:10.1038/sj.onc.1211024 · Cited by 861 · cited 1×
“This includes blocking invasion of tumour cells by inhibiting matrix metalloproteinase-9 activation [15], activating growth suppressors through phosphorylation of retinoblastoma protein (pRb) resulting in G0/G1 arrest in prostate cancer cells [16] and inhibiting cancer stem-cell activity [17].”
(1999) · Diabetes Care · doi:10.2337/diacare.22.4.623 · Cited by 725
Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides
Birsoy, K., Possemato, R., Lorbeer, F. K., Bayraktar, E. C., Thiru, P., Yucel, B., Wang, T., Chen, W. W., Clish, C. B., & Sabatini, D. M. (2014) · Nature · doi:10.1038/nature13110 · Cited by 710
Anti-inflammatory effects of metformin irrespective of diabetes status
Cameron, A. R., Morrison, V. L., Levin, D., Mohan, M., Forteath, C., Beall, C., McNeilly, A. D., Balfour, D. J. K., Savinko, T., Wong, A. K. F., et al. (2016) · Circulation Research · doi:10.1161/circresaha.116.308445 · Cited by 704
Hilgendorf, C., Ahlin, G., Seithel, A., Artursson, P., Ungell, A.-L., & Karlsson, J. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.014902 · Cited by 583
Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis
Noto, H., Goto, A., Tsujimoto, T., & Noda, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033411 · Cited by 566
Metformin and the Risk of Cancer
Suissa, S., & Azoulay, L. (2012) · Diabetes Care · doi:10.2337/dc12-0788 · Cited by 531
Investigating Metformin for Cancer Prevention and Treatment: The End of the Beginning
Pollak, M. N. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0263 · Cited by 507
Long-Term Metformin Use Is Associated With Decreased Risk of Breast Cancer
Bodmer, M., Meier, C., Krähenbühl, S., Jick, S. S., & Meier, C. R. (2010) · Diabetes Care · doi:10.2337/dc09-1791 · Cited by 466
Gandini, S., Puntoni, M., Heckman-Stoddard, B. M., Dunn, B. K., Ford, L., DeCensi, A., & Szabo, E. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0424 · Cited by 457
Self-citationMetformin as an adjuvant treatment for cancer: a systematic review and meta-analysis
Coyle, C., Cafferty, F. H., Vale, C., & Langley, R. E. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw410 · Cited by 452
Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review
Franciosi, M., Lucisano, G., Lapice, E., Strippoli, G. F. M., Pellegrini, F., & Nicolucci, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071583 · Cited by 428
Bao, B., Wang, Z., Ali, S., Ahmad, A., Azmi, A. S., Sarkar, S. H., Banerjee, S., Kong, D., Li, Y., Thakur, S., et al. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0299 · Cited by 337
Higurashi, T., Hosono, K., Takahashi, H., Komiya, Y., Umezawa, S., Sakai, E., Uchiyama, T., Taniguchi, L., Hata, Y., Uchiyama, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00565-3 · Cited by 331
Metformin Suppresses Colorectal Aberrant Crypt Foci in a Short-term Clinical Trial
Hosono, K., Endo, H., Takahashi, H., Sugiyama, M., Sakai, E., Uchiyama, T., Suzuki, K., Iida, H., Sakamoto, Y., Yoneda, K., et al. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0186 · Cited by 311
Hadad, S., Iwamoto, T., Jordan, L., Purdie, C., Bray, S., Baker, L., Jellema, G., Deharo, S., Hardie, D. G., Pusztai, L., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1612-1 · Cited by 293
Cancer Risk Associated with Use of Metformin and Sulfonylurea in Type 2 Diabetes: A Meta-Analysis
Soranna, D., Scotti, L., Zambon, A., Bosetti, C., Grassi, G., Catapano, A., La Vecchia, C., Mancia, G., & Corrao, G. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0462 · Cited by 274
Association of metformin use with cancer incidence and mortality: A meta-analysis
Zhang, P., Li, H., Tan, X., Chen, L., & Wang, S. (2013) · Cancer Epidemiology · doi:10.1016/j.canep.2012.12.009 · Cited by 270
Zhou, M., Xia, L., & Wang, J. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.015495 · Cited by 251
Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial
Bonanni, B., Puntoni, M., Cazzaniga, M., Pruneri, G., Serrano, D., Guerrieri-Gonzaga, A., Gennari, A., Trabacca, M. S., Galimberti, V., Veronesi, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.3769 · Cited by 244
Self-citationMetformin in early breast cancer: a prospective window of opportunity neoadjuvant study
Niraula, S., Dowling, R. J. O., Ennis, M., Chang, M. C., Done, S. J., Hood, N., Escallon, J., Leong, W. L., McCready, D. R., Reedijk, M., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2223-1 · Cited by 238
Chen, L., Shu, Y., Liang, X., Chen, E. C., Yee, S. W., Zur, A. A., Li, S., Xu, L., Keshari, K. R., Lin, M. J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314939111 · Cited by 237
Metformin Targets Central Carbon Metabolism and Reveals Mitochondrial Requirements in Human Cancers
Liu, X., Romero, I. L., Litchfield, L. M., Lengyel, E., & Locasale, J. W. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.09.005 · Cited by 236
Insulin-Lowering Effects of Metformin in Women with Early Breast Cancer
Goodwin, P. J., Pritchard, K. I., Ennis, M., Clemons, M., Graham, M., & Fantus, I. G. (2008) · Clinical Breast Cancer · doi:10.3816/cbc.2008.n.060 · Cited by 228
Metformin: A Therapeutic Opportunity in Breast Cancer
Gonzalez-Angulo, A. M., & Meric-Bernstam, F. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1805 · Cited by 209
Thakkar, B., Aronis, K. N., Vamvini, M. T., Shields, K., & Mantzoros, C. S. (2013) · Metabolism · doi:10.1016/j.metabol.2013.01.014 · Cited by 186
Stevens, R. J., Ali, R., Bankhead, C. R., Bethel, M. A., Cairns, B. J., Camisasca, R. P., Crowe, F. L., Farmer, A. J., Harrison, S., Hirst, J. A., et al. (2012) · Diabetologia · doi:10.1007/s00125-012-2653-7 · Cited by 161
Zhang, Z., & Li, S. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12267 · Cited by 149
Wu, L., Zhu, J., Prokop, L. J., & Murad, M. H. (2015) · Scientific Reports · doi:10.1038/srep10147 · Cited by 144
Schuler, K., Rambally, B. S., DiFurio, M. J., Sampey, B. P., Gehrig, P. A., Makowski, L., & Bae-Jump, V. L. (2014) · Cancer Medicine · doi:10.1002/cam4.353 · Cited by 142
Effects of metformin on endometrial cancer cell growth in vivo: A preoperative prospective trial
Mitsuhashi, A., Kiyokawa, T., Sato, Y., & Shozu, M. (2014) · Cancer · doi:10.1002/cncr.28853 · Cited by 139
Mitsuhashi, A., Sato, Y., Kiyokawa, T., Koshizaka, M., Hanaoka, H., & Shozu, M. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv539 · Cited by 136
Han, G., Gong, H., Wang, Y., Guo, S., & Liu, K. (2014) · Cancer Biology & Therapy · doi:10.4161/15384047.2014.987021 · Cited by 113
Zhao, D., Long, X., Lu, T., Wang, T., Zhang, W., Liu, Y. G., Cui, X., Dai, H., Xue, F., & Xia, Q. (2014) · International Journal of Cancer · doi:10.1002/ijc.29305 · Cited by 91
Measuring the biological effect of presurgical metformin treatment in endometrial cancer
Sivalingam, V. N., Kitson, S., McVey, R. J., Roberts, C., Pemberton, P. W., Gilmour, K., Ali, S., Renehan, A. G., Kitchener, H. C., & Crosbie, E. J. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.453 · Cited by 87
Saitoh, R., Sugano, K., Takata, N., Tachibana, T., Higashida, A., Nabuchi, Y., & Aso, Y. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000026423.48583.e2 · Cited by 85
Presurgical Trial of Metformin in Overweight and Obese Patients with Newly Diagnosed Breast Cancer
Kalinsky, K. M., Crew, K. D., Refice, S., Xiao, T., Wang, A., Feldman, S. M., Taback, B., Ahmad, A., Cremers, S., Hibshoosh, H. H., et al. (2014) · Cancer Investigation · doi:10.3109/07357907.2014.889706 · Cited by 84
A pilot ‘window of opportunity’ neoadjuvant study of metformin in localised prostate cancer
Joshua, A. M., Zannella, V. E., Downes, M. R., Bowes, B., Hersey, K. M., Koritzinsky, M., Schwab, M. G., Hofmann, U., Evans, A., van der Kwast, T., et al. (2014) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2014.20 · Cited by 77
Zhou, P., Li, B., Liu, F.-R., Zhang, M., Wang, Q., Li, Y., Xu, C., Liu, Y., Yao Zong, Y. U. A. N., & Li, D. (2017) · Oncotarget · doi:10.18632/oncotarget.15692 · Cited by 77
Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial
Curry, J., Johnson, J. M., Tassone, P. T., Domingo‐Vidal, M., Menezes, D. W., Sprandio, J. D., Mollaee, M., Cotzia, P., Birbe, R., Lin, Z., et al. (2017) · The Laryngoscope · doi:10.1002/lary.26489 · Cited by 74
Metformin and prostate cancer mortality: A meta-analysis
Stopsack, K. H., Ziehr, D. R., Rider, J. R., & Giovannucci, E. L. (2016) · Cancer Causes & Control · doi:10.1007/s10552-015-0687-0 · Cited by 72
Campagnoli, C., Pasanisi, P., Abbà, C., Ambroggio, S., Biglia, N., Brucato, T., Colombero, R., Danese, S., Donadio, M., Venturelli, E., et al. (2012) · Clinical Breast Cancer · doi:10.1016/j.clbc.2012.03.004 · Cited by 68
Ma, S., Zheng, Y., Zhou, P., Xiao, Y., & Tan, H. (2016) · Oncotarget · doi:10.18632/oncotarget.11033 · Cited by 67
Repurposing old drugs to chemoprevention: the case of metformin
Heckman‐Stoddard, B. M., Gandini, S., Puntoni, M., Dunn, B. K., DeCensi, A., & Szabo, E. M. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.009 · Cited by 66
Self-citationRaval, A. D., Thakker, D., Vyas, A., Salkini, M., Madhavan, S. S., & Sambamoorthi, U. (2015) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2014.52 · Cited by 66
He, X.-K., Su, T.-T., Si, J.-M., & Sun, L.-M. (2016) · Medicine · doi:10.1097/md.0000000000002749 · Cited by 59
Metformin therapy associated with survival benefit in lung cancer patients with diabetes
Wan, G., Yu, X., Chen, P., Wang, X., Pan, D., Wang, X., Li, L., Cai, X., & Cao, F. (2016) · Oncotarget · doi:10.18632/oncotarget.8881 · Cited by 59
Yang, T., Yang, Y., & Liu, S. (2015) · Journal of Breast Cancer · doi:10.4048/jbc.2015.18.3.264 · Cited by 58
Tian, R., Zhang, Y.-G., Wu, Z., Liu, X., Yang, J.-W., & Ji, H. L. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1412-x · Cited by 55
The Effect of Metformin on Mortality Following Cancer among Patients with Diabetes
Lega, I. C., Shah, P. S., Margel, D., Beyene, J., Rochon, P. A., & Lipscombe, L. L. (2014) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0327 · Cited by 53
Nie, Z., Zhu, H., & Gu, M. (2016) · Pharmaceutical Biology · doi:10.1080/13880209.2016.1176057 · Cited by 53
Chak, A., Buttar, N. S., Foster, N. R., Seisler, D. K., Marcon, N. E., Schoen, R. E., Cruz-Correa, M. R., Falk, G. W., Sharma, P., Hur, C., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.08.040 · Cited by 50
Metformin use and the risk of colorectal adenoma: A systematic review and meta-analysis
Jung, Y. S., Park, C. H., Eun, C. S., Park, D. I., & Han, D. S. (2017) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13639 · Cited by 49
Cai, H., Zhang, Y., Han, T. K., Everett, R. S., & Thakker, D. R. (2016) · International Journal of Cancer · doi:10.1002/ijc.29965 · Cited by 46
Perez-Lopez, F. R., Pasupuleti, V., Gianuzzi, X., Palma-Ardiles, G., Hernandez-Fernandez, W., & Hernandez, A. V. (2017) · Maturitas · doi:10.1016/j.maturitas.2017.04.001 · Cited by 45
Colon neoplasia in patients with type 2 diabetes on metformin: A meta-analysis
Rokkas, T., & Portincasa, P. (2016) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2016.05.027 · Cited by 34
Cited by
The mechanisms of action of metformin
Rena, G., Hardie, D. G., & Pearson, E. R. (2017) · Diabetologia · doi:10.1007/s00125-017-4342-z · Cited by 2,287
Obesity and cancer risk: Emerging biological mechanisms and perspectives
Avgerinos, K. I., Spyrou, N., Mantzoros, C. S., & Dalamaga, M. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.001 · Cited by 1,567
Benefits of Metformin in Attenuating the Hallmarks of Aging
Kulkarni, A. S., Gubbi, S., & Barzilai, N. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.04.001 · Cited by 766
Metformin: update on mechanisms of action and repurposing potential
Foretz, M., Guigas, B., & Viollet, B. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00833-4 · Cited by 699
Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus
Foretz, M., Guigas, B., & Viollet, B. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0242-2 · Cited by 686
Metadata
- Authors
- Heckman-Stoddard, B. M., DeCensi, A., Sahasrabuddhe, V. V., & Ford, L. G.
- Venue
- Diabetologia
- Published
- 2017-08-03
- Volume
- 60
- Issue
- 9
- Pages
- 1639-1647
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2742254242
- Cited by
- 297
- References
- 62
- FWCI
- 9.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.